tradingkey.logo
tradingkey.logo
Search

Neogenomics Inc

NEO
Add to Watchlist
14.970USD
+0.380+2.60%
Close 07/01, 16:00ETQuotes delayed by 15 min
1.95BMarket Cap
LossP/E TTM

More Details of Neogenomics Inc Company

NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The Company offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing; interpretation and consultative services; molecular and NGS testing; comprehensive technical and professional services offering; clinical trials and research; validation laboratory services, and oncology data solutions. It operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, and others.

Neogenomics Inc Info

Ticker SymbolNEO
Company nameNeogenomics Inc
IPO dateDec 10, 2012
CEOZook (Antony P)
Number of employees2200
Security typeOrdinary Share
Fiscal year-endDec 10
Address9490 Neogenomics Way
CityFORT MYERS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code33912
Phone12397680600
Websitehttps://neogenomics.com/
Ticker SymbolNEO
IPO dateDec 10, 2012
CEOZook (Antony P)

Company Executives of Neogenomics Inc

Name
Name/Position
Position
Shareholding
Change
Mr. Jeffrey Scott (Jeff) Sherman
Mr. Jeffrey Scott (Jeff) Sherman
Chief Financial Officer
Chief Financial Officer
220.01K
+0.96%
Mr. Warren Stone
Mr. Warren Stone
President, Chief Operating Officer
President, Chief Operating Officer
164.03K
+3.45%
Mr. Stephen Michael Kanovsky
Mr. Stephen Michael Kanovsky
Independent Director
Independent Director
75.42K
+30.60%
Dr. Neil Gunn
Dr. Neil Gunn
Independent Director
Independent Director
51.18K
+45.09%
Ms. Felicia Williams
Ms. Felicia Williams
Independent Director
Independent Director
30.24K
+76.32%
Ms. Marjorie C. Green
Ms. Marjorie C. Green
Independent Director
Independent Director
22.96K
--
Ms. Lynn A. Tetrault, J.D.
Ms. Lynn A. Tetrault, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Alison L. Hannah, M.D.
Dr. Alison L. Hannah, M.D.
Independent Director
Independent Director
--
--
Mr. Michael A. Kelly
Mr. Michael A. Kelly
Lead Independent Director
Lead Independent Director
--
--
Mr. David B. Perez
Mr. David B. Perez
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Jeffrey Scott (Jeff) Sherman
Mr. Jeffrey Scott (Jeff) Sherman
Chief Financial Officer
Chief Financial Officer
220.01K
+0.96%
Mr. Warren Stone
Mr. Warren Stone
President, Chief Operating Officer
President, Chief Operating Officer
164.03K
+3.45%
Mr. Stephen Michael Kanovsky
Mr. Stephen Michael Kanovsky
Independent Director
Independent Director
75.42K
+30.60%
Dr. Neil Gunn
Dr. Neil Gunn
Independent Director
Independent Director
51.18K
+45.09%
Ms. Felicia Williams
Ms. Felicia Williams
Independent Director
Independent Director
30.24K
+76.32%
Ms. Marjorie C. Green
Ms. Marjorie C. Green
Independent Director
Independent Director
22.96K
--

FAQs

Who are the top five shareholders of Neogenomics Inc?

The top five shareholders of Neogenomics Inc are: Mr. Jeffrey Scott (Jeff) Sherman

How many institutions hold shares of Neogenomics Inc (NEO)?

As of 2026Q1, 564 institutions hold shares of Neogenomics Inc, with a combined market value of approximately 156.61M, accounting for 120.32% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 7515333.00.

What is the biggest source of revenue for Neogenomics Inc?

In 2026Q1, the Clinical Services-Client direct billing business generated the highest revenue for Neogenomics Inc, amounting to 518.84M and accounting for 71.34% of total revenue.